Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial
Key Points
The aim is to evaluate the effectiveness of multimodal ctDNA profiling in detecting minimal residual disease (MRD) in ovarian cancer.
Conducted the MITO16a/MaNGO-OV2 trial
Utilized ctDNA profiling techniques
Assessed MRD detection and risk stratification in participants
Identified ctDNA as a sensitive method for MRD detection
Enhanced prognostic assessment beyond traditional clinical factors
Supported non-invasive monitoring for therapeutic management
Abstract
Together, these findings establish multimodal ctDNA profiling as a sensitive, non-invasive strategy for MRD detection and longitudinal surveillance in advanced EOC, refining prognostic assessment beyond clinical and surgical factors while paving the way for precision-guided therapeutic management.
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial | Synapse